search
Back to results

A Study of Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis

Primary Purpose

Rheumatoid Arthritis

Status
Completed
Phase
Phase 2
Locations
Japan
Study Type
Interventional
Intervention
adalimumab
adalimumab
adalimumab
placebo
Sponsored by
Abbott
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Rheumatoid Arthritis

Eligibility Criteria

20 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Meet ACR criteria for diagnosis of active RA and have at both screening and baseline visits >10 swollen joints, >12 tender joints.
  • Subjects must have failed prior treatment with one or more DMARDs.
  • A negative (serum) pregnancy test for all female subjects of child-bearing potential at screening and a negative (urine) pregnancy test prior to study drug administration.
  • Body weight less than or equal to 100 kg

Exclusion Criteria:

  • A history of, or current, acute inflammatory joint disease of different origin from RA.
  • Prior treatment with any TNF antagonist, including adalimumab.
  • Any ongoing chronic or active infection or any major episode of infection requiring hospitalization or treatment with IV antibiotics.
  • Unstable ischemic heart disease, active inflammatory bowel disease, active peptic ulcer disease, recent stroke or any poorly controlled medical condition.

Sites / Locations

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

Placebo Comparator

Arm Label

20 mg

40 mg

80 mg

Placebo

Arm Description

20 mg adalimumab eow

40 mg adalimumab eow

80 mg adalimumab eow

Placebo eow

Outcomes

Primary Outcome Measures

ACR20

Secondary Outcome Measures

ACR20
ACR50
ACR70

Full Information

First Posted
March 27, 2008
Last Updated
March 27, 2008
Sponsor
Abbott
Collaborators
Eisai Limited
search

1. Study Identification

Unique Protocol Identification Number
NCT00647491
Brief Title
A Study of Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis
Study Type
Interventional

2. Study Status

Record Verification Date
March 2008
Overall Recruitment Status
Completed
Study Start Date
February 2004 (undefined)
Primary Completion Date
June 2005 (Actual)
Study Completion Date
August 2005 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Abbott
Collaborators
Eisai Limited

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The primary objective of this study is to evaluate the safety, efficacy and pharmacokinetics of three doses of adalimumab in adult Japanese subjects with RA

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Rheumatoid Arthritis

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
352 (Actual)

8. Arms, Groups, and Interventions

Arm Title
20 mg
Arm Type
Experimental
Arm Description
20 mg adalimumab eow
Arm Title
40 mg
Arm Type
Experimental
Arm Description
40 mg adalimumab eow
Arm Title
80 mg
Arm Type
Experimental
Arm Description
80 mg adalimumab eow
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo eow
Intervention Type
Biological
Intervention Name(s)
adalimumab
Other Intervention Name(s)
ABT-D2E7, Humira
Intervention Description
20 mg sc eow
Intervention Type
Biological
Intervention Name(s)
adalimumab
Other Intervention Name(s)
ABT-D2E7, Humira
Intervention Description
40 mg sc eow
Intervention Type
Biological
Intervention Name(s)
adalimumab
Other Intervention Name(s)
ABT-D2E7, Humira
Intervention Description
80 mg sc eow
Intervention Type
Biological
Intervention Name(s)
placebo
Intervention Description
placebo sc eow
Primary Outcome Measure Information:
Title
ACR20
Time Frame
Week 24
Secondary Outcome Measure Information:
Title
ACR20
Time Frame
Week12
Title
ACR50
Time Frame
Weeks 12 and 24
Title
ACR70
Time Frame
Weeks 12 and 24

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Meet ACR criteria for diagnosis of active RA and have at both screening and baseline visits >10 swollen joints, >12 tender joints. Subjects must have failed prior treatment with one or more DMARDs. A negative (serum) pregnancy test for all female subjects of child-bearing potential at screening and a negative (urine) pregnancy test prior to study drug administration. Body weight less than or equal to 100 kg Exclusion Criteria: A history of, or current, acute inflammatory joint disease of different origin from RA. Prior treatment with any TNF antagonist, including adalimumab. Any ongoing chronic or active infection or any major episode of infection requiring hospitalization or treatment with IV antibiotics. Unstable ischemic heart disease, active inflammatory bowel disease, active peptic ulcer disease, recent stroke or any poorly controlled medical condition.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Shigeki Hashimoto, Ph.D.
Organizational Affiliation
Abbott
Official's Role
Study Director
Facility Information:
City
Aichi
Country
Japan
City
Chiba
Country
Japan
City
Ehime
Country
Japan
City
Fukui
Country
Japan
City
Fukuoka
Country
Japan
City
Gunma
Country
Japan
City
Hokkaido
Country
Japan
City
Hyogo
Country
Japan
City
Ibaraki
Country
Japan
City
Ishikawa
Country
Japan
City
Kagoshima
Country
Japan
City
Kanagawa
Country
Japan
City
Kyoto
Country
Japan
City
Miyagi
Country
Japan
City
Nagano
Country
Japan
City
Nagasaki
Country
Japan
City
Niigata
Country
Japan
City
Okayama
Country
Japan
City
Osaka
Country
Japan
City
Saitama
Country
Japan
City
Shizuoka
Country
Japan
City
Tochigi
Country
Japan
City
Tokushima
Country
Japan
City
Tokyo
Country
Japan
City
Toyama
Country
Japan

12. IPD Sharing Statement

Citations:
PubMed Identifier
27338778
Citation
Burmester GR, Landewe R, Genovese MC, Friedman AW, Pfeifer ND, Varothai NA, Lacerda AP. Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis. Ann Rheum Dis. 2017 Feb;76(2):414-417. doi: 10.1136/annrheumdis-2016-209322. Epub 2016 Jun 23.
Results Reference
derived

Learn more about this trial

A Study of Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis

We'll reach out to this number within 24 hrs